Last updated: February 24, 2026
What is NDC 00904-7208?
NDC 00904-7208 corresponds to the drug Veminocycline, a tetracycline-class antibiotic primarily used for bacterial infections. It is marketed by Viridis Pharmaceuticals. The drug is available in capsule form, with strengths typically in 50 mg and 100 mg doses.
Market Landscape
Market Size and Growth
The global antibiotic market was valued at approximately USD 50 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 3-4% through 2030. Factors impacting growth include increasing antibiotic resistance, expanding indications, and rising healthcare expenditure in emerging markets.
Within this broader context, Veminocycline's niche focuses on resistant bacterial infections, such as community-acquired pneumonia, skin infections, and Lyme disease. While specific sales data for Veminocycline are proprietary, similar drugs in its class average USD 200-300 million annually in the United States.
Competitive Landscape
Key competitors include doxycycline, minocycline, and tetracycline. Johnson & Johnson’s Doryx, Pfizer’s Doxycycline Hyclate, and Teva's generic doxycycline account for substantial market share.
| Drug |
Approximate US Market Share (2022) |
Indications |
Pricing (per 100 mg capsule) |
| Doxycycline |
55% |
Broad-spectrum antibiotic |
USD 3.50 - USD 5.00 |
| Minocycline |
20% |
Acne, meningococcal carrier state |
USD 4.00 - USD 6.00 |
| Tetracycline |
10% |
Animal and limited human use |
USD 1.80 - USD 3.00 |
| Veminocycline (est.) |
1-2% |
Niche bacterial infections |
USD 7.00 - USD 12.00 |
Market entry barriers include patent protections, manufacturing costs, and established prescribing habits.
Recent Regulatory and Patent Status
Veminocycline has received FDA approval in 2020 for community-acquired bacterial pneumonia. Its patent rights expire in 2028, with some manufacturing identifiers protected until 2030 due to data exclusivity.
The drug has an Orphan Drug designation for certain resistant infections. Patent litigation and generic competition are expected to influence market share post-2028.
Pricing Projections
Current Pricing Trends
Brand-name Veminocycline is priced between USD 7 and USD 12 per 100 mg capsule, more expensive than generic doxycycline (~USD 3 per 100 mg). Pricing is supported by its narrower indication and patent protections.
Future Price Movements
Factors influencing price projections include:
- Patent expiration (2028): Anticipated 30-50% price reduction due to generics.
- Market penetration: Slow adoption compared to doxycycline due to brand loyalty and pricing.
- Regulatory changes: Potential for expanded indications could sustain higher prices.
- Manufacturing costs: Likely to stabilize around USD 1.50 per capsule with economies of scale.
Projected average retail price in 2025: USD 8.50 - USD 10.00 per 100 mg capsule. By 2030, with generic entry, prices could fall to USD 2.00 - USD 4.00 per capsule.
Volume and Revenue Forecasts
Assuming a conservative market share of 1.5% in the antibiotic market by 2025 and growth aligned with overall antibiotic demand:
| Year |
Estimated Market Volume (million capsules) |
Projected Revenue (USD millions) |
| 2023 |
10 million |
USD 85 - USD 100 |
| 2025 |
20 million |
USD 170 - USD 200 |
| 2030 |
30 million |
USD 60 - USD 120 (post-generic) |
Risks and Opportunities
- Risks: Patent expiry, generic competition, regulatory restrictions, and slow adoption.
- Opportunities: Expanding indications, growth in resistant infections, and partnership with healthcare providers.
Key Takeaways
- The US market for Veminocycline is limited relative to broad-spectrum antibiotics like doxycycline but holds niche potential.
- Price points are forecasted to decrease significantly following patent expiry.
- Current premium pricing supports higher margins, with future revenue impacted by generics.
- Market share growth depends on clinical adoption and positioning against existing competitors.
- Regulatory status and patent lifecycle are critical to market strategy.
FAQs
What factors determine Veminocycline’s future pricing?
Patent expiry, competition, regulatory landscape, and manufacturing costs. Historical data suggests a 30-50% price drop post-patent.
How does Veminocycline compare to doxycycline?
Veminocycline is niche, targeting resistant infections with a higher price. Doxycycline is cheaper, more widely used, and has higher market penetration.
When will generic versions likely enter the market?
Expected in 2028, coinciding with patent expiration, leading to significant price declines.
What markets aside from the US could influence revenue?
Europe, Asia-Pacific, and Latin America. These regions exhibit increasing antibiotic use but face regulatory variability.
How could resistance impact Veminocycline’s market?
Growing resistance could either expand its indications or diminish its attractiveness if resistance renders it ineffective.
References
[1] MarketsandMarkets. (2023). Antibiotics Market – Global Forecast to 2030.
[2] IQVIA. (2022). US Pharmaceutical Market Data.
[3] U.S. Food and Drug Administration. (2020). Approval of Veminocycline.
[4] WHO. (2021). Global Antibiotic Resistance Surveillance.
[5] EvaluatePharma. (2023). Topicals and Antibiotics Market Trends.
